3 years ago

Cytomos Secures £1.6 Million to Advance Cell Analysis Platform

  • Edinburgh-based life science company Cytomos has raised £1.6 million in seed funding to further develop its cell analysis platform, Cytomos Dielectric Spectroscopy (CDS)

  • The platform has applications in drug development, bioprocessing, and cell and gene therapy manufacturing

  • The funding round was led by existing investor Archangels, alongside Scottish Enterprise and the University of Edinburgh's venture investment fund, Old College Capital.

      • ProblemTechnology

      "Developing and manufacturing life-saving biologic therapies is a complex and expensive process, often hindered by the lack of efficient and affordable cell analysis tools."

      Solution

      "Cytomos has developed a novel process analytical technology platform called Cytomos Dielectric Spectroscopy (CDS) that provides a low-cost, real-time, highly scalable, and easy-to-operate solution for single-cell and label-free analysis. This platform can be used in drug development, bioprocessing, vaccine production, and cell and gene therapy manufacturing."

      Covered on